SCHEMBL30516368

SCHEMBL30516368

CC(C)(C)OC(=O)N1CCN(c2cccc(NCc3ccc(Cl)c(Cl)c3)c2N)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
KCNQ2 O43526 1/20 0.45
ACHE P22303 1/20 0.44
MAPT P10636 2/20 0.43
LMNA P02545 2/20 0.43
GAA P10253 1/20 0.43
MCOLN3 Q8TDD5 1/20 0.43
KDM1A O60341 1/20 0.43
TACR1 P25103 3/20 0.42
MET P08581 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP2C19 P33261 1/20 0.41
SMARCA2 P51531 1/20 0.41
SMARCA4 P51532 1/20 0.41
PBRM1 Q86U86 1/20 0.41
CCNT1 O60563 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21301986 1.00 MAPK8 (0.47) MAPK8SMN1; SMN2HTTNPSR1KCNQ2
SCHEMBL21301987 0.92 P2RX7 (0.46) MAPK8SMN1; SMN2HTTNPSR1ACHE
SCHEMBL30516387 0.92 P2RX7 (0.46) MAPK8SMN1; SMN2HTTNPSR1ACHE
SCHEMBL21301932 0.90 ACHE (0.47) MAPK8SMN1; SMN2HTTNPSR1KCNQ2
SCHEMBL30516377 0.90 ACHE (0.47) MAPK8SMN1; SMN2HTTNPSR1KCNQ2
SCHEMBL4615974 0.89 MAPK8 (0.46) MAPK8SMN1; SMN2HTTNPSR1KCNQ2
SCHEMBL21301974 0.89 SMN1; SMN2 (0.46) MAPK8SMN1; SMN2HTTNPSR1ACHE
SCHEMBL30516367 0.89 SMN1; SMN2 (0.46) MAPK8SMN1; SMN2HTTNPSR1ACHE
SCHEMBL21302003 0.87 KCNQ2 (0.45) MAPK8SMN1; SMN2HTTNPSR1KCNQ2
SCHEMBL30516382 0.87 KCNQ2 (0.45) MAPK8SMN1; SMN2HTTNPSR1KCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12319682-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2025-06-03 US disclosed
US-20240287056-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS Adamed Pharma S.A (PL) 2024-08-29 US disclosed
CN-112041300-B Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists 阿达梅德制药公司 2023-07-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12319682-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists HTR2A, HTR6, HTR2C MAPK8 4595/4885SMN1; SMN2 3365/4885HTT 149/4885
US-20240287056-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS HTR2A, HTR6, HTR2C MAPK8 4481/4885SMN1; SMN2 3307/4885HTT 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.